Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Pharma
Johnson & Johnson's Tecvayli struts its stuff as a monotherapy
In a multiple myeloma trial, Tecvayli cut the risk of disease progression or death by 71% over standard care in patients resistant to CD38 therapy.
Kevin Dunleavy
Jan 15, 2026 10:15am
2025's top biopharma M&A deals
Jan 12, 2026 3:00am
J&J reveals US drug pricing deal and plans to build 2 US plants
Jan 9, 2026 10:49am
Lilly, J&J launches top Clarivate's Drugs to Watch 2026 report
Jan 7, 2026 9:28am
Bayer sues Moderna, J&J and Pfizer/BioNTech over COVID vax tech
Jan 7, 2026 8:35am
J&J will appeal $1.5B verdict in record-breaking talc award
Dec 23, 2025 11:06am
